trial summary

TrialResults-center.org

Menu

Heart failure

All type of patients: 8 trials - WESG - EMTG - ESG - Lardoux - ESSENTIAL (I and II) - Cowley - EMOTE - EMPOWER

Enoximone vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Sudden death	1.53 [0.34 6.90]	p=1.00	0	266	2	WESG,EMTG,
Worsening heart failure	0.91 [0.30 2.73]	p=1.00	0	102	1	EMTG,
Transplantation	no data
Arrhythmia	1.50 [0.06 37.80]	p=1.00	0	105	1	ESG,
Vertigo	0.52 [0.09 2.97]	p=1.00	0	102	1	EMTG,
Death from any cause or hospitalization for heart failure	0.97 [0.84 1.12]	p=1.00	0	904	1	ESSENTIAL (I and II),
myocardial infarction (fatal and non fatal)	3.12 [0.12 78.45]	p=1.00	0	102	1	EMTG,
cardiac death	1.78 [0.93 3.40]	p=1.00	0	253	2	EMTG,Cowley,
All cause death	1.00 [0.88 1.14]	p=1.00	0	1918	6	WESG,EMTG,ESG,Lardoux,ESSENTIAL (I and II),Cowley,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

enoximone vs placebo (on top metoprolol)

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Sudden death	no data
Worsening heart failure	no data
Transplantation	no data
Arrhythmia	no data
Vertigo	no data
Death from any cause or hospitalization for heart failure	no data
myocardial infarction (fatal and non fatal)	no data
cardiac death	no data
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Modal title

- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy -